We align with patient advocates, academia, and independent researchers on pioneering science supporting new and improved solutions that may transform the lives of patients and shape the future of our company. In 2015, we entered into a research collaboration with the Grace Science Foundation and the Warren Family Research Center for Drug Discovery and Development at the University of Notre Dame on the development of a novel therapeutic for patients with NGLY1 deficiency.
Learn more about this partnership.
We seek opportunities to acquire late-stage clinical assets or commercial-ready medicines that fit within our strategy of addressing rare diseases with significant unmet medical needs.
We invite potential partners who share our goals to contact us at firstname.lastname@example.org.